- Home
- ATRC vs RCKT Comparison
ATRC vs RCKT Comparison
Compare ATRC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRC
- RCKT
- Stock Information
- Founded
- ATRC 2000
- RCKT 1999
- Country
- ATRC United States
- RCKT United States
- Employees
- ATRC N/A
- RCKT N/A
- Industry
- ATRC Medical/Dental Instruments
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- ATRC Health Care
- RCKT Health Care
- Exchange
- ATRC Nasdaq
- RCKT Nasdaq
- Market Cap
- ATRC 1.1B
- RCKT 1.3B
- IPO Year
- ATRC 2005
- RCKT N/A
- Fundamental
- Price
- ATRC $35.34
- RCKT $10.74
- Analyst Decision
- ATRC Strong Buy
- RCKT Strong Buy
- Analyst Count
- ATRC 9
- RCKT 11
- Target Price
- ATRC $41.78
- RCKT $50.27
- AVG Volume (30 Days)
- ATRC 465.9K
- RCKT 1.7M
- Earning Date
- ATRC 02-13-2025
- RCKT 02-24-2025
- Dividend Yield
- ATRC N/A
- RCKT N/A
- EPS Growth
- ATRC N/A
- RCKT N/A
- EPS
- ATRC N/A
- RCKT N/A
- Revenue
- ATRC $447,573,000.00
- RCKT N/A
- Revenue This Year
- ATRC $17.75
- RCKT N/A
- Revenue Next Year
- ATRC $13.44
- RCKT $240,645.72
- P/E Ratio
- ATRC N/A
- RCKT N/A
- Revenue Growth
- ATRC 17.56
- RCKT N/A
- 52 Week Low
- ATRC $18.94
- RCKT $10.28
- 52 Week High
- ATRC $39.05
- RCKT $31.47
- Technical
- Relative Strength Index (RSI)
- ATRC 61.92
- RCKT 34.49
- Support Level
- ATRC $31.00
- RCKT $10.28
- Resistance Level
- ATRC $36.15
- RCKT $13.30
- Average True Range (ATR)
- ATRC 1.50
- RCKT 0.69
- MACD
- ATRC 0.55
- RCKT -0.05
- Stochastic Oscillator
- ATRC 88.19
- RCKT 17.43
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.